NEW YORK, Sept. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ:INSM) between March 18, 2013 and June 8, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired Insmed securities between March 18, 2013 and June 8, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/insmed-incorporated.
The complaint alleges that, throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the data supporting Insmed’s European marketing authorization application (“MAA”) for lead product candidate ARIKAYCE was not likely to be approved by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease, and (2) therefore ARIKAYCE’S approval by the EMA and subsequent commercialization in Europe were less likely and/or imminent than Insmed led investors to believe.
On June 8, 2016, Insmed announced it had withdrawn its MAA for ARIKAYCE from the EMA, revealing that the Committee for Medicinal Products for Human Use indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval.
If you suffered a loss in Insmed you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/insmed-incorporated.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



